{"id":11387,"date":"2024-08-14T12:30:57","date_gmt":"2024-08-14T12:30:57","guid":{"rendered":"https:\/\/www.friendly-bartik.94-130-216-58.plesk.page\/flec-sl\/"},"modified":"2024-12-16T13:09:17","modified_gmt":"2024-12-16T13:09:17","slug":"flec-sl","status":"publish","type":"page","link":"https:\/\/www.af-net.eu\/en\/flec-sl\/","title":{"rendered":"Flec-SL"},"content":{"rendered":"\n
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n\n\n\n
\n

Flec-SL<\/strong>-AFNET 3<\/h2>\n\n\n\n
<\/div>\n\n\n\n

Targeted Pharmacological Reversal of Electrical Remodeling After Cardioversion.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n
\n

Study design<\/strong><\/h2>\n\n\n\n
<\/div>\n\n\n\n

Prospective, randomized, controlled, open label, parallel group multi-center investigator-initiated trial.<\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
Inclusion Criteria<\/strong><\/h5>\n\n\n\n

\"\" Documented persistent atrial fibrillation<\/p>\n\n\n\n

\"\" Age of 18 years<\/p>\n\n\n\n

\"\" Documented oral anticoagulation (INR \u2265 2) for at least three weeks prior to inclusion, or exclusion of left atrial thrombi by trans-esophageal echocardiography<\/p>\n\n\n\n

\"\" Written informed consent of the patient<\/p>\n<\/div>\n\n\n\n

\n
Exclusion Criteria<\/strong><\/h5>\n\n\n\n

\"\" Current therapy with antiarrhythmic agents of class I and class III other than study medication flecainide. Such antiarrhythmic treatment must be stopped five half lives prior to enrolment. Five half-lives correspond to 48 hours for almost all antiarrhythmic agents. For details regarding a specific agent, this information can be obtained through the internet at www.rote-liste.de or from the information of the specific compound.<\/p>\n\n\n\n

\"\" Long-term therapy with amiodarone within the last 6 months prior to inclusion<\/p>\n\n\n\n